drugset / Trial / NCT07630103
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, open-label, multicenter, randomized, parallel Phase II clinical trial. This study aims to investigate the efficacy and safety of trastuzumab rezetecan or trastuzumab deruxtecan in HER2 positive advanced/metastastic breast cancer
Timeline
- Start
- 2026-06
- Primary completion
- 2031-06
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | 4.8 mg/kg | Intravenous |
| Comparator | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |